Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 17 Beta Hydroxyestr 4 En 3 One 17 Decanoate
2. 17 Beta-hydroxyestr-4-en-3-one 17-decanoate
3. 19 Nor 4 Androstene 17 Beta Ol 3 One 17 Decanoate
4. 19 Nortestosterone Decanoate
5. 19-nor-4-androstene-17 Beta-ol-3-one 17-decanoate
6. 19-nortestosterone Decanoate
7. Decadurabolin
8. Decadurobolin
9. Retabolil
10. Retabolyl
1. 360-70-3
2. Retabolil
3. 19-nortestosterone Decanoate
4. Norandrostenolone Decanoate
5. Deca-hybolin
6. Nortestosterone Decanoate
7. Hybolin Decanoate
8. Estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17b)-
9. Nandrolone Decanoate Ciii
10. Chebi:7467
11. [(8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] Decanoate
12. Retabolyl
13. Nandrobolic L.a.
14. 19-norandrostenolone Decanoate
15. Naboline
16. 19-nortestosterone 17-decanoate
17. Ncgc00159403-02
18. Salistoperm
19. Dimapolan
20. Palactin
21. Rougerol
22. Superbolan
23. Ziremilon
24. Anaboline Depot
25. Anabolin Depot
26. Ndrolone-d
27. H45187t098
28. Dsstox_cid_3352
29. Dsstox_rid_76988
30. Dsstox_gsid_23352
31. (8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl Decanoate
32. Estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17.beta.)-
33. (1s,2r,10r,11s,14s,15s)-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl Decanoate
34. Cas-360-70-3
35. Drg 0264
36. Einecs 206-639-3
37. Brn 2228051
38. 17beta-hydroxyestr-4-en-3-one Decanoate
39. Deca-durobolin
40. 17-beta-hydroxyestr-4-en-3-one Decanoate
41. Estr-4-en-3-one, 17-((1-oxodecyl)oxy)-, (17.beta.)-
42. 17beta-hydroxyestr-4-en-3-one 17-decanoate
43. Unii-h45187t098
44. (17-beta)-17-((1-oxodecyl)oxy)estr-4-en-3-one
45. Nandrolone Decanoate [usan:usp:jan]
46. Deca-durabolin (tn)
47. Nandrolonedecanoate
48. (17beta)-3-oxoestr-4-en-17-yl Decanoate
49. Nandrolone 17beta-decanoate
50. Estr-4-en-3-one, 17-beta-hydroxy-, Decanoate
51. Schembl27975
52. Chembl1200946
53. Dtxsid7023352
54. Nandrolone Decanoate (jan/usp)
55. Estr-4-en-3-one, 17-((1-oxodecyl)oxy)-, (17beta)-
56. Nandrolone Decanoate [mi]
57. Nandrolone Decanoate [jan]
58. Nandrolone Decanoate [usan]
59. Zinc8214619
60. Nandrolone Decanoate [vandf]
61. Tox21_111638
62. Mfcd00135100
63. Nandrolone Decanoate [mart.]
64. Nandrolone Decanoate [who-dd]
65. Akos025311438
66. Tox21_111638_1
67. 19-nortestosterone-17.beta.-decanoate
68. Ac-1484
69. Cs-4613
70. Db08804
71. Gs-3155
72. Ncgc00159403-04
73. Ncgc00263561-01
74. Hy-13698
75. Nandrolone Decanoate [ep Impurity]
76. Nandrolone Decanoate [orange Book]
77. Nandrolone Decanoate [ep Monograph]
78. Nandrolone Decanoate Ciii [usp-rs]
79. Nandrolone Decanoate [usp Monograph]
80. 17b-hydroxyestr-4-en-3-one Decanoate.
81. C08154
82. D00955
83. 360n703
84. A823112
85. Q16634231
86. 17.beta.-hydroxyestr-4-en-3-one 17-decanoate
87. Nandrolone Decanoate, European Pharmacopoeia (ep) Reference Standard
88. Nandrolone Decanoate, United States Pharmacopeia (usp) Reference Standard
89. Nandrolone Decanoate For Peak Identification, European Pharmacopoeia (ep) Reference Standard
90. Nandrolone Decanoate For System Suitability, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 428.6 g/mol |
|---|---|
| Molecular Formula | C28H44O3 |
| XLogP3 | 7.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 10 |
| Exact Mass | 428.32904526 g/mol |
| Monoisotopic Mass | 428.32904526 g/mol |
| Topological Polar Surface Area | 43.4 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 680 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Nandrolone decanoate |
| Drug Label | A sterile oleaginous solution containing per mL: Nandrolone Decanoate 100 mg with Benzyl Alcohol 10% as solubilizer/preservative, in Sesame Oil q.s., and Nandrolone Decanoate 200 mg with Benzyl Alcohol 5% as solubilizer/preservative, in Sesame Oil q.... |
| Active Ingredient | Nandrolone decanoate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 200mg/ml |
| Market Status | Prescription |
| Company | Pharmaforce |
| 2 of 2 | |
|---|---|
| Drug Name | Nandrolone decanoate |
| Drug Label | A sterile oleaginous solution containing per mL: Nandrolone Decanoate 100 mg with Benzyl Alcohol 10% as solubilizer/preservative, in Sesame Oil q.s., and Nandrolone Decanoate 200 mg with Benzyl Alcohol 5% as solubilizer/preservative, in Sesame Oil q.... |
| Active Ingredient | Nandrolone decanoate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 200mg/ml |
| Market Status | Prescription |
| Company | Pharmaforce |
Nandrolone decanoate is indicated in the management of anemia of renal insufficiency. In Canada, it is also indicated as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis.
Nandrolone decanoate is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis. It has a long duration of action as it is given every 3-4 weeks, and a wide therapeutic window as acute overdoses are rare. Patients should be counselled regarding the risks of giving this drug to patients with cardiac, renal, or hepatic diseases.
Anabolic Agents
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Absorption
A 50 mg intramuscular dose of nandrolone decanoate reaches a mean Cmax 2.14 ng/mL, with a mean Tmax of 30 hours, and a mean AUC of 400 h\*ng/mL. A 100 mg intramuscular dose of nandrolone decanoate reaches a mean Cmax 4.26 ng/mL, with a mean Tmax of 30 hours, and a mean AUC of 862 h\*ng/mL. A 150 mg intramuscular dose of nandrolone decanoate reaches a mean Cmax 5.16 ng/mL, with a mean Tmax of 72 hours, and a mean AUC of 1261 h\*ng/mL.
Route of Elimination
Nandrolone decanoate is eliminated as urinary metabolites, however data regarding elimination in the feces are not readily available. Data in cattle shows that [nandrolone] is 30% eliminated in the feces.
Clearance
50 mg, 100 mg, and 150 mg doses of nadrolone decanoate had mean apparent clearances of 80.0 L/h, 74.3 L/h, and 76.2 L/h respectively.
Nandrolone decanoate is hydrolyzed to [nandrolone], possibly by PDE7B. Nandrolone is further metabolized to the urinary metabolites 19-norandrosterone, 19-noretiocholanolone, and 19-norepiandrosterone. 19-norandrosterone is 3-O-glucuronidated by UGT2B7, UGT 1A4, UGT2B4, UGT1A3, and UGT1A1. 19-noretiocholanolone is 3-O-glucuronidated by UGT2B7, UGT2B4, UGT1A4, UGT1A10, UGT1A3, and UGT1A1.
Nandrolone decanoate has an absorption half life of 6 days and an elimination half life of 4.3 hours. Alternate studies have shown that nandrolone decanoate has a terminal half life of 7.1, 11.7, and 11.8 hours for doses of 50, 100, and 150 mg respectively.
Nandrolone decanoate is hydrolyzed to [nandrolone], possibly by PDE7B. Nandrolone is brought into cells by receptor mediated endocytosis, where it interacts with the androgen receptor. After binding to the androgen receptor, a conformational change occurs, the androgen receptor enters the nucleus, dimerizes, and can then bind to segments of DNA to regulate transcription. Androgens can also regulate transcription through activation of ERK, Akt, and MAPK; or binding to and competitively inhibiting transcription factors.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Parenteral
Solubilizers
Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
